Claassen, Daniel O.
Adler, Charles H.
Hewitt, L. Arthur
Gibbons, Christopher
Article History
Received: 6 April 2018
Accepted: 15 August 2018
First Online: 25 August 2018
Ethics approval and consent to participate
: The study was performed in accordance with ethical standards (e.g., 1964 Helsinki Declaration and later amendments or the comparable). Respondents were selected from individuals who agreed to participate in Harris Poll online surveys or were members of certain advocacy organizations who actively decided to participate in the survey. For research in which participants are intended to remain anonymous, Harris Poll uses tools and methods to ensure that there is no reasonable possibility of identifying an individual participant in the reports created (e.g., individual responses collected are combined to produce “aggregated” reports). As an anonymous survey, the study was exempt from ethics approval based on Code of Federal Regulations Title 45, Part 46, Subpart A, Section 46.101b, Category 2 criteria.
: Not applicable.
: DOC receives grant support from the National Institutes of Health and the Michael J. Fox Foundation for Parkinson’s Research; is a site investigator for clinical trials sponsored by Vaccinex, AbbVie, CHDI, and Auspex/Teva Neuroscience; and has received personal remuneration from Lundbeck, Teva Neuroscience, Acadia, and AbbVie for consulting, advisory board participation, and speaking honoraria. CHA has received research funding from the National Institutes of Health and the Michael J. Fox Foundation for Parkinson’s Research and consulting fees from Acadia, Acorda, Adamas, Cynapsus, Jazz, Lundbeck, Minerva, Neurocrine, and Sunovion. LAH is an employee of Lundbeck Medical Affairs. CG has served on advisory boards for Lundbeck and Pfizer and on data safety monitoring boards for Janssen and Astellas, and has received grants from Grifols and Celgene.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.